Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-17
2005-05-17
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06894060
ABSTRACT:
A method of treating dermal lesions caused by envenomation comprising applying a therapeutically effective amount of an immune response modifier compound selected from the group consisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazolopyridine amines, oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines to the site of the lesion is disclosed.
REFERENCES:
patent: 3314941 (1967-04-01), Littell et al.
patent: 3917624 (1975-11-01), Abu El-Haj et al.
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4929624 (1990-05-01), Gerster et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster
patent: 5268376 (1993-12-01), Gerster
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5444065 (1995-08-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5494916 (1996-02-01), Lindstrom et al.
patent: 5585612 (1996-12-01), Harp, Jr.
patent: 5605899 (1997-02-01), Gerster et al.
patent: 5627281 (1997-05-01), Nikolaides et al.
patent: 5644063 (1997-07-01), Lindstrom et al.
patent: 5648516 (1997-07-01), Nikolaides et al.
patent: 5714608 (1998-02-01), Gerster
patent: 5741909 (1998-04-01), Gerster et al.
patent: 5886006 (1999-03-01), Nikolaides et al.
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 5977366 (1999-11-01), Gerster et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 0 894 797 (1998-02-01), None
patent: 9-208584 (1997-08-01), None
patent: WO 9309119 (1993-05-01), None
patent: WO 9748704 (1997-12-01), None
patent: WO 9817279 (1998-04-01), None
patent: WO 0009506 (2000-02-01), None
patent: WO 0040228 (2000-07-01), None
patent: WO 0076505 (2000-12-01), None
patent: WO 0076518 (2000-12-01), None
Leynadier et al., Journal of Allergy and Clinical Immunology, 1997; 99(6 pt 1): 851-853.*
Bitterman-Deutsch et al., HAREFUAH, 1990; 119(5-6):137-139.*
Mosbech et al., Ugeskrift for Laeger, 1991;153(44):3067-3071.*
Binder, Medical Toxicology and Adverse Drug Experience, 1989; 4(3):163-173.*
Auerbach et al., Journal of Emergency Medicine, 1987;5(6):487-491.*
Wozniak, et al, “The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate1,2, A New and Convenient Amination Method.”Journal of the Royal Netherlands Chemical Society,102, pp 511-513, Dec. 12, 1983.
Brennan, et al, “Automated Bioassay of Interferons in Micro-test Plates”,Biotechniqes,Jun./Jul., 78, 1983.
Testerman, et al, “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology,vol. 58, pp. 365-372, Sep. 1995.
Bachman, et al, “Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline”,J. Org. Chem,15, pp 1278-1284 (1950).
Jain, et al, “Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines”,J. Med. Chem.,11, pp 87-92 (1968).
Baranov, et al.,Chem. Abs.85, 94371, (1976).
Berényi, et al, “Ring Transformation of Condensed Dihydro-as-triazines”,J. Heterocyclic Chem.,18, pp 1537-1540 (1981).
G.S. Wasserman and P.C. Anderson, “Loxoscelism and Necrotic Arachnidism,”J. Toxicol.-Clin. Toxicol.,21(4&5), 451-472 (1983-84).
“Dapsone (diaminodiphenylsulphone, DDS),”Clinical Toxicology Review,vol. 21, No. 9, pp. 1-3 (Jun. 1999).
Merigian KS, Blaho K. Envenomation from the brown recluse spider: Review of mechanism and treatment options. American Journal of Therapeutics 1996; 3: 724-734.
Borkan J, Gross E, Lubin Y, Oryan I. An outbreak of venomous spider bites in a citrus grove. American Journal of Tropical Medicine & Hygiene 1995; 52: 228-230.
Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM, Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J.Am.Acad.Dermatol. 1998; 38: 230-239.
Gendron BP. Loxosceles reclusa envenomation. American Journal of Emergency Medicine 1990; 8: 51-54.
Stack LB. Lacrodectus mactans. N.Engl.J.Med. 1997; 336: 1649.
Wilson DC, King LE, Jr. Spiders and spider bites. Dermatologic Clinics 1990; 8: 277-286.
Wright SW, Wrenn KD, Murray L, Seger D. Clinical presentation and outcome of brown recluse spider bite. Annals of Emergency Medicine 1997; 30: 28-32.
Cole III, Wesley RE, King JL. Brown recluse spider envenomation of the eyelid: An animal model. Ophthalmic Plastic & Reconstructive Surgery 1995; 11: 153-164.
Broughton IIG. Management of the brown recluse spider bite to the glans penis. Military Medicine 1996; 161: 627-629.
Beilman GJ, Winslow CL, Teslow TW. Experimental brown spider bite in the guinea pig: Results of treatment with dapsone or hyperbaric oxygen. Journal of Wilderness Medicine 1994; 5: 287-294.
Maynor ML, Moon RE, Klitzman B, Fracica PJ, Canada A. Brown recluse spider envenomation: A prospective trial of hyperbaric oxygen therapy. Academic Emergency Medicine 1997; 4: 184-192.
Hobbs GD, Anderson AR, Greene TJ, Yealy DM. Comparison of hyperbaric oxygen and dapsone therapy for Loxosceles envenomation. Academic Emergency Medicine 1996; 3: 758-761.
Rees RS, Altenbern DP, Lynch JB, King LE, Jr. Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Annals of Surgery 1985; 202: 659-663.
Ottonello L, Dapino P, Scirocco MC, Balbi A, Bevilacqua M, Dallegri F. Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clinical Science 1995; 88: 331-336.
Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. Journal of Leukocyte Biology 1997; 62: 827-836.
Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. Journal of Investigative Dermatology 1992; 98: 135-140.
Phillips S, Kohn M, Baker D, et al. Therapy of brown spider envenomation: A controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Annals of Emergency Medicine 1995; 25: 363-368.
Majeski JA, Stinnett JD, Alexander JW, Durst GG, Sr. Action of venom from the brown recluse spider (Loxosceles reclusa) on human neutrophils. Toxicon 1977; 15: 423-427.
Luger TA, Schwarz T. Evidence for an epidermal cytokine network. [Review] [54 refs]. Journal of Investigative Dermatology 1990; 95: 100S-104S.
Patel KD, Modur V, Zimmerman GA, Prescott SM, McIntyre TM. The necrotic venom of the brown recluse spider induces dysregulated endothelial cell-dependent neutrophil activation. Differential induction of GM-CSF, IL-8, and E-selectin expression. Journal of Clinical Investigation 1994; 94: 631-642.
Gomez HF, Miller MJ, Trachy JW, Marks RM, Warren JS. Intradermal anti-loxosceles Fab fragments attenuate dermonecrotic arachnidism. Academic Emergency Medicine 1999; 6: 1195-1202.
Gibson SJ, Imbertson LM, Wagner TL, et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. Journal of Interferon & Cytokine Research 1995; 15: 537-545.
Miller R, Birmachu W, Gerster J, et al. Imiquimod: cytokine induction and antiviral activity. Antiviral News 1995; 3: 111-113.
Tomai MA, Birmachu W, Case MT, et al. Imiquimod: in vivo and in vitro characteristics and toxicology. In: Aly R, Beutner KR, Maibach H, eds. Cutaneous infection and therapy, New York: Marcel Dekkar, Inc., 1997: 405-415.
Sams HH, Dunnick CA, Smith ML, King LE, Jr. Necrotic arachnidism. J Am Acad Dermatol 2001; 44:561-73.
Smith, CW, Micks DW. The role of polymorp
3M Innovative Properties Company
Gram Christopher D.
Hui Sen-ming
Padmanabhan Sreeni
Sprague Robert W.
LandOfFree
Method for the treatment of dermal lesions caused by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of dermal lesions caused by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of dermal lesions caused by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464213